| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CTRB |
| WB Predicted band size | 28 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CTRB1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CTRB1抗体的3篇示例文献(注：内容为模拟概括，建议通过学术数据库验证具体信息)：
---
1. **文献名称**: *"Development of a monoclonal antibody specific for human chymotrypsinogen B (CTRB1) and its application in pancreatic disease diagnosis"*
**作者**: Zhang Y, et al.
**摘要**: 该研究开发了一种高特异性的抗人CTRB1单克隆抗体，通过ELISA和免疫组化验证其在胰腺组织及血清中的检测能力。结果显示，CTRB1抗体可用于辅助诊断慢性胰腺炎和胰腺癌，尤其在区分良性/恶性病变中表现潜力。
2. **文献名称**: *"Autoantibodies against CTRB1 in type 1 diabetes: a novel biomarker for disease progression"*
**作者**: Johnson RL, et al.
**摘要**: 研究首次报道1型糖尿病患者血清中存在CTRB1自身抗体，并通过队列研究分析其与胰岛β细胞功能衰退的相关性，提示CTRB1抗体可能作为疾病进展的早期预测标志物。
3. **文献名称**: *"Proteomic profiling of pancreatic enzymes reveals CTRB1 as a potential therapeutic target in pancreatic ductal adenocarcinoma"*
**作者**: Lee S, et al.
**摘要**: 利用CTRB1抗体进行蛋白质组学分析，发现胰腺导管腺癌(PDAC)组织中CTRB1表达显著下调，并通过体外实验证实其表达缺失促进肿瘤侵袭，为靶向治疗提供新思路。
---
**提示**：实际文献需通过PubMed、Web of Science等平台以关键词“CTRB1 antibody”或“chymotrypsinogen B antibody”检索，并优先选择近5年发表、高被引的原创研究。
Chymotrypsinogen B1 (CTRB1) is a pancreatic protease precursor primarily synthesized in the acinar cells of the pancreas. It is enzymatically inactive until cleaved into its active form, chymotrypsin B, which plays a critical role in digesting dietary proteins in the small intestine. CTRB1 is part of a family of serine proteases, sharing structural homology with other chymotrypsinogens like CTRC and CTRA. Dysregulation of CTRB1 has been implicated in pancreatic disorders, including chronic pancreatitis, pancreatic cancer, and diabetes, making it a biomarker of interest in both research and clinical settings.
CTRB1 antibodies are immunological tools designed to detect and quantify CTRB1 protein expression. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA) to study CTRB1's tissue distribution, expression levels, and involvement in disease mechanisms. Polyclonal and monoclonal CTRB1 antibodies are generated using immunogenic peptide sequences specific to CTRB1. ensuring target specificity. Recent studies also explore CTRB1's interaction with other proteases and its potential role in modulating inflammatory pathways, highlighting its therapeutic relevance. Validation of CTRB1 antibodies includes testing for cross-reactivity with related proteases to confirm specificity, which is critical for accurate experimental outcomes in pancreatic research.
×
